Should I buy or sell Aquestive Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares. View AQST analyst ratings or view top-rated stocks .

What is Aquestive Therapeutics' stock price target for 2024?

5 Wall Street analysts have issued 12-month price objectives for Aquestive Therapeutics' shares. Their AQST share price targets range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 77.8% from the stock's current price. View analysts price targets for AQST or view top-rated stocks among Wall Street analysts .

How have AQST shares performed in 2024?

Aquestive Therapeutics' stock was trading at $2.02 at the beginning of the year. Since then, AQST shares have increased by 122.8% and is now trading at $4.50. View the best growth stocks for 2024 here .

When is Aquestive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our AQST earnings forecast .

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.04. The company earned $13.21 million during the quarter, compared to analyst estimates of $11.79 million.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $48.0 million-$51.0 million, compared to the consensus revenue estimate of $48.1 million.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Dynavax Technologies (DVAX) , ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , Organigram (OGI) , Novan (NOVN) , Outlook Therapeutics (OTLK) and KushCo (KSHB) .

When did Aquestive Therapeutics IPO?

Aquestive Therapeutics (AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AQST

Aquestive Therapeutics (AQST) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free AQST Stock Alerts

$4.50

+0.58 (+14.80%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.93
▼
$4.51
50-Day Range: $2.51
▼
$6.09
52-Week Range: $1.15
▼
$6.23

Volume: 5.78 million shs
Average Volume: 2.20 million shs
Market Capitalization: $329.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Aquestive Therapeutics alerts:

Aquestive Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 77.8% Upside
$8.00 Price Target
Short Interest: Healthy
3.10% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.21
Based on 3 Articles This Week
Insider Trading: Selling Shares
$429,750 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.36) to ($0.32) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.27 out of 5 stars

Medical Sector

510th out of 918 stocks

Pharmaceutical Preparations Industry

221st out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Aquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aquestive Therapeutics has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.10% of the outstanding shares of Aquestive Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Aquestive Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aquestive Therapeutics has recently decreased by 2.16%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Aquestive Therapeutics does not currently pay a dividend.
Dividend Growth
Aquestive Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AQST.

2.3

News and Social Media Coverage

News Sentiment
Aquestive Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Aquestive Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 26 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
MarketBeat Follows
26 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aquestive Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $429,750.00 in company stock.
Percentage Held by Insiders
Only 8.39% of the stock of Aquestive Therapeutics is held by insiders.
Percentage Held by Institutions
Only 32.45% of the stock of Aquestive Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aquestive Therapeutics are expected to grow in the coming year, from ($0.36) to ($0.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aquestive Therapeutics is -32.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aquestive Therapeutics is -32.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Aquestive Therapeutics Stock (NASDAQ:AQST)

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

AQST Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AQST Stock News Headlines

March 20, 2024 | insidertrades.com

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Insider Alexander Mark Schobel Sells 50,000 Shares

April 17, 2024 | investorplace.com

Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 12, 2024 | globenewswire.com

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

April 12, 2024 | americanbankingnews.com

Piper Sandler Begins Coverage on Aquestive Therapeutics (NASDAQ:AQST)

April 11, 2024 | msn.com

Piper starts Aquestive at overweight, cites allergy reaction treatment

April 11, 2024 | msn.com

Aquestive Therapeutics a new overweight at Piper on oral film products

April 8, 2024 | americanbankingnews.com

Brokers Set Expectations for Aquestive Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:AQST)

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 25, 2024 | globenewswire.com

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

March 20, 2024 | msn.com

Aquestive Therapeutics slumps 13%, prices $75M offering

March 20, 2024 | investorplace.com

Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today?

March 19, 2024 | globenewswire.com

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

March 19, 2024 | finance.yahoo.com

Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 50,000 Shares of Aquestive ...

March 19, 2024 | globenewswire.com

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

March 15, 2024 | msn.com

5 Growth Stocks Under $50 for March 2024

March 15, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)

March 14, 2024 | globenewswire.com

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

March 12, 2024 | finance.yahoo.com

Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 25,000 Shares of Aquestive ...

March 11, 2024 | realmoney.thestreet.com

Aquestive Therapeutics price target raised by $1 at H.C. Wainwright, here's why

March 8, 2024 | seekingalpha.com

Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Aquestive Therapeutics Inc Reports Full Year 2023 Financial Results

March 7, 2024 | realmoney.thestreet.com

Aquestive Therapeutics price target raised by $5 at Lake Street, here's why

March 7, 2024 | insidermonkey.com

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Aquestive Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

March 7, 2024 | finance.yahoo.com

Q4 2023 Aquestive Therapeutics Inc Earnings Call

March 6, 2024 | finanznachrichten.de

Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

See More Headlines

Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AQST
CUSIP: N/A
CIK: 1398733
Web: www.aquestive.com
Phone: (908) 941-1900
Fax: N/A
Employees: 135
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $10.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +82.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,870,000.00
Net Margins: -15.56%
Pretax Margin: -15.07%
Return on Equity: N/A
Return on Assets: -13.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.24
Quick Ratio: 1.87

Sales & Book Value

Annual Sales: $50.58 million
Price / Sales: 6.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.59) per share
Price / Book: -2.75

Miscellaneous

Outstanding Shares: 73,300,000
Free Float: 67,151,000
Market Cap: $321.05 million
Optionable: Optionable
Beta: 2.87

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Daniel Barber (Age 48)
CEO, President & Director
Comp: $925.35k
Mr. Alexander Mark Schobel (Age 65)
Chief Innovation & Technology Officer
Comp: $672.69k
Ms. Lori J. Braender BSBA (Age 68)
Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $678.76k
Mr. A. Ernest Toth Jr. (Age 65)
Chief Financial Officer
Comp: $679.9k
Ms. Cassie Jung (Age 45)
Senior Vice President of Operations
Mr. Peter E. Boyd (Age 58)
Senior Vice President of IT, HR & Communications
Dr. Gary H. Slatko M.D. (Age 66)
MBA, Chief Medical Officer
Dr. Stephen Wargacki (Age 46)
Senior VP of Research & Development
Dr. Carl N. Kraus M.D. (Age 54)
Chief Medical Officer
Mr. Robert Charles Arnold
VP of Finance, Controller & Assistant Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AQST Stock Analysis - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings or view top-rated stocks.
What is Aquestive Therapeutics' stock price target for 2024?: 5 Wall Street analysts have issued 12-month price objectives for Aquestive Therapeutics' shares. Their AQST share price targets range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 77.8% from the stock's current price.
View analysts price targets for AQST or view top-rated stocks among Wall Street analysts.
How have AQST shares performed in 2024?: Aquestive Therapeutics' stock was trading at $2.02 at the beginning of the year. Since then, AQST shares have increased by 122.8% and is now trading at $4.50.
View the best growth stocks for 2024 here.
When is Aquestive Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our AQST earnings forecast.
How were Aquestive Therapeutics' earnings last quarter?: Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.04. The company earned $13.21 million during the quarter, compared to analyst estimates of $11.79 million.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?: Aquestive Therapeutics updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $48.0 million-$51.0 million, compared to the consensus revenue estimate of $48.1 million.
What other stocks do shareholders of Aquestive Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).
When did Aquestive Therapeutics IPO?: Aquestive Therapeutics (AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.
How do I buy shares of Aquestive Therapeutics?: Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AQST) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aquestive Therapeutics (AQST) Stock Price, News & Analysis

Aquestive Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Aquestive Therapeutics Stock (NASDAQ:AQST)

AQST Stock Price History

AQST Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AQST Stock Analysis - Frequently Asked Questions

Overall MarketRank^™